Entera Bio (ENTX) Total Liabilities (2017 - 2026)
Entera Bio's (ENTX) quarterly Total Liabilities came in at $2.4 million in Q1 2026, up 9.95% YoY from $2.2 million in Q1 2025, and down 15.56% on a QoQ basis from $2.9 million in Q4 2025.
Entera Bio (ENTX) Total Liabilities (2017 - 2026) Analysis & Trends
Entera Bio (ENTX) has 10 years of Total Liabilities data on file, last reported at $2.4 million in Q1 2026.
- Quarterly Total Liabilities rose 9.95% year-over-year to $2.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 million (up 9.95% YoY) and the FY2025 annual result came in at $2.9 million, up 120.76% from the prior year.
- Total Liabilities slipped to $2.4 million in Q1 2026, from $2.9 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $2.9 million in Q4 2025 to a low of $1.2 million in Q3 2022.
- A 5-year average of $1.9 million and a median of $1.8 million in 2022 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2022 — Total Liabilities tumbled 59.88% — and 2025, when it soared 120.76%.
- Tracing ENTX's Total Liabilities over 5 years: stood at $1.4 million in 2022, then climbed by 0.44% to $1.4 million in 2023, then declined by 5.0% to $1.3 million in 2024, then soared by 120.76% to $2.9 million in 2025, then retreated by 15.56% to $2.4 million in 2026.
- The last three Total Liabilities figures came in at $2.4 million (Q1 2026), $2.9 million (Q4 2025), and $2.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 77.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.00 Bn | 59.82 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 56.27 Bn | 51.13 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.00 Bn | 36.90 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.60 Bn | 28.29 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.68 Bn | 9.29 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.43 Bn | 26.27 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.34 Bn | 26.51 Bn | - | 10.03 Bn |
| 10 | Entera Bio | 164.47 Mn | 153.16 Mn | - | 12.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.21 Mn |
| Mar 31, 2026 | 2.44 Mn |
| Dec 31, 2025 | 2.89 Mn |
| Sep 30, 2025 | 2.17 Mn |
| Jun 30, 2025 | 2.41 Mn |
| Mar 31, 2025 | 2.22 Mn |
| Dec 31, 2024 | 1.31 Mn |
| Sep 30, 2024 | 1.29 Mn |
| Jun 30, 2024 | 1.50 Mn |
| Mar 31, 2024 | 1.38 Mn |
| Dec 31, 2023 | 1.38 Mn |
| Sep 30, 2023 | 2.33 Mn |
| Jun 30, 2023 | 2.21 Mn |
| Mar 31, 2023 | 1.53 Mn |
| Dec 31, 2022 | 1.37 Mn |
| Sep 30, 2022 | 1.23 Mn |
| Jun 30, 2022 | 1.82 Mn |
| Mar 31, 2022 | 2.57 Mn |
| Dec 31, 2021 | 3.42 Mn |
| Jun 30, 2021 | 3.62 Mn |